Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063203 · ClinicalTrials.gov registry record · Phase 2
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03063203 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 17 participants.
The verdict
NCT03063203, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
In this study, the investigators seek to determine whether decitabine therapy can improve outcomes, specifically overall survival this selected subset of acute myeloid leukemia (AML) patients with the poorest prognosis based on refractoriness to induction treatment and high risk genetic mutations.
Interventions
- DRUG Decitabine
- PROCEDURE Peripheral blood draw
- PROCEDURE Buccal swab
- PROCEDURE Skin biopsy
- PROCEDURE Bone marrow biopsy/aspirate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03063203
The ClinicalTrials.gov registry entry for NCT03063203 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Decitabine is the first listed.
NCT03063203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03063203 about?
NCT03063203 is a clinical study titled "Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia". In this study, the investigators seek to determine whether decitabine therapy can improve outcomes, specifically overall survival this selected subset of acute myeloid leukemia (AML) patients with the poorest prognosis based on refractoriness to induction treatment and high risk genetic mutations.
What is the current status of trial NCT03063203?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2017-07-14. Estimated completion is 2022-03-16.
What interventions are being tested in trial NCT03063203?
The interventions under investigation include: Decitabine (DRUG), Peripheral blood draw (PROCEDURE), Buccal swab (PROCEDURE), Skin biopsy (PROCEDURE), Bone marrow biopsy/aspirate (PROCEDURE).
Who is sponsoring clinical trial NCT03063203?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.